| ［1］Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998.Thorax,1998,53(7):536-548.［2］Snider DE Jr, Cohn DL, Davidson PT, et al. Standard therapy for tuberculosis 1985. Chest, 1985,87(2 Suppl):117S-124S.［3］Horsburgh CR Jr, Feldman S, Ridzon R,et al. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis, 2000,31(3):633-639.［4］Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med,2003,167(4):603-622.［5］Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Short-course therapy for tuberculosis in infants and children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. CMAJ,1994,150(8):1233-1239.［6］张秋滨，闫红，刘波. 皮质激素在结核病治疗中的合理应用. 黑龙江医学，2005，29（1）:30-31.［7］马玙,朱莉贞，潘毓萱. 结核病. 北京：人民卫生出版社，2006：254-262.［8］Pardridge WM. Drug targeting to the brain. Pharm Res, 2007,24(9):1733-1744.［9］World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003. Geneva: WHO,2003.［10］Donald PR, Schoeman JF, Van Zyl LE, et al. Intensive short course chemotherapy in the management of tuberculous meningitis. Int J Tuberc Lung Dis,1998, 2(9):704-711.［11］Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect, 2009, 59(3):167-187.［12］彭卫生,王英年，肖成志. 新编结核病学. 2版.北京：中国医药科技出版社，2003:34-247.［13］Dutt AK, Stead WW. Treatment of extrapulmonary tuberculosis. Semin Respir Infect, 1989,4(3):225-231.［14］余秉真，闫世明，邹志艳,等. 205例成人结核性脑膜炎治疗探讨. 中华结核和呼吸杂志，1992,15（2）:79-80.［15］严碧涯，端木宏谨.结核病学.北京：北京出版社，2003.［16］邹级谦.复治肺结核标准化疗方案之我见.中华结核和呼吸杂志，2009，32（8）：564-565.［17］杜建，徐彩红，李琦,等.不同类型治疗方案治疗耐多药结核病效果文献分析.中国防痨杂志，2010,32（8）：421-426.［18］中国防痨协会.耐药结核病化学治疗指南（2009）.中国防痨杂志，2010,32（4）：181-198.［19］Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis, 2009,49(7):1080-1082.［20］Katiyar SK, Bihari S, Prakash S, et al. A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis,2008,12(2):139-145.［21］Falzon D,Jaramillo E,Schünemann HJ,et al.WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J,2011，38(3):516-528.［22］屠德华. 从指南的制定谈规范耐多药结核病的化学治疗.中华结核和呼吸杂志，2010,33（7）：483484.［23］韩利军，闫世明，赵云虹,等. 20例成人耐药结核性脑膜炎临床观察. 中国防痨杂志，2010,32（4）:224-226.［24］牟君，霍康，谢鹏.皮质激素辅助治疗结核性脑膜炎的研究现状.中国防痨杂志，2008,30（4）：352-354.［25］Evans DJ.The use of adjunctive corticosteroids in the treatment of pericardial, pleural and meningeal tuberculosis:do they improve outcome? Respir Med,2008,102(6):793-800.［26］Simmons CP,Thwaites GE,Quyen NT,et al.The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or immune responses.J Immunol,2005, 175(1):579-590.［27］王焱烽，陈冰，姚茂元. 糖皮质激素冲击治疗Ⅲ期结核性脑膜炎疗效观察. 临床医学，2009，29（12）：21-22.［28］Fitch MT, van de Beek D. Drug Insight:steroids in CNS infectious diseases——new indications for an old therapy. Nat Clin Pract Neurol, 2008,4(2): 97-104.［29］闫世明，邹志艳，安龙浩，等. 大剂量短程地塞米松治疗结核性脑膜炎临床探讨. 中国防痨杂志，1994，16（4）：155-157.［30］董庆林，井西伟，岳红，等.糖皮质激素辅助治疗成人结核性脑膜炎的疗效观察.临床神经病学杂志，2004,17（1）：42-43.［31］McGee S, Hirschmann J. Use of corticosteroids in treating infectious diseases. Arch Intern Med, 2008, 168(10): 1034-1046.［32］Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev, 2008，(1):CD002244.［33］闫世明，孙秀娟，邹志艳,等. 不同剂量地塞米松治疗结核性脑膜炎的对比观察. 中华结核和呼吸杂志，1995，18（4）：236.［34］闫世明，潘桂芬，杨家道. 结核性脑膜炎患者甲状腺肾上腺皮质性腺激素水平的研究. 中华结核和呼吸杂志，1998，21（7）：433.［35］邵平波，汪思敏，佟士秀,等. 成人结核性脑膜炎445例临床分析. 中华结核和呼吸系统疾病杂志，1980，3：131. |
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
